Source: Annual Congress 2013 –The role of hormones and cytokines in lung injury
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Tsavlis, A. Tzoumaka, G. Kokaraki, K. Koliakos-Kouzi, A. Papadopoulou, D. Koutsonikolas, E. Spandou (Thessaloniki, Greece). The attenuating effect of erythropoietin (EPO) on the expression of myeloperoxidase (MPO) in bleomycin-induced pulmonary fibrosis in rats. Eur Respir J 2013; 42: Suppl. 57, 3927

Member's Comments

No comment yet.

Related content which might interest you: 17(R)-resolvin D1 ameliorates bleomycin-induced pulmonary fibrosis in mice via decreasing MCP-1 mRNA Source: International Congress 2015 – Interstitial lung diseases II Year: 2015 Erythropoietin (EPO) inhibits the immunohistochemical expression of lysyl oxidase (LOX) in bleomycin (BLM)-induced pulmonary fibrosis (PF) in rats Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease Year: 2015 Infliximab, an anti-tumor necrosis factor-α attenuates bleomycin-induced pulmonary fibrosis in rats Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease Year: 2015 Comparison of expression of napsin A and surfactant protein D in bleomycin-induced pulmonary fibrosis mouse model Source: Annual Congress 2013 –Diffuse parenchymal lung disease I Year: 2013 Nintedanib reduces bleomycin-induced lung inflammation and fibrosis in mice Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases Year: 2013 Effects of NecroX compounds on bleomycin-induced pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016 Effect of pirfenidone (PFD) on cytokine/chemokine release from alveolar macrophages (AMs) in interstitial lung diseases (ILD): Preliminary results Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 The immunomodulatory effect of protein S in pulmonary fibrosis Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 PBI-compound, a novel first-in-class anti-fibrotic compound, reduces lung fibrosis in the bleomycin-induced lung fibrosis model: A comparative study with pirfenidone Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases Year: 2013 Specialized-proresolving mediators and trancriptomic signatures in bleomycin-induced lung fibrosis Source: International Congress 2016 – Common mechanisms in lung development and fibrosis Year: 2016 Olodaterol attenuates bleomycin induced lung fibrosis in mice Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action Year: 2016 Matrix metalloproteinase-2 is protective in bleomycin-induced pulmonary fibrosis Source: International Congress 2015 – Animal studies of asthma and other inflammatory conditions Year: 2015 Nintedanib inhibits fibroblast activation and ameliorates pulmonary and dermal fibrosis in models of systemic sclerosis (SSc) Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 17(R)-resolvin D1 attenuates bleomycin-induced lung fibrosis in mice Source: Annual Congress 2013 –Novel in vitro and animal models to study lung diseases Year: 2013 A transient receptor potential melastin-2 deficiency significantly worsens the fibrotic response to bleomycin in mice Source: Annual Congress 2013 –The role of hormones and cytokines in lung injury Year: 2013 Collagen V activation and matrix extracellular remodeling mediated pulmonary fibrosis in experimental models of bleomycin and 3-5-di-tert-4-hidroxitoluene Source: Annual Congress 2013 –Growth factors at the crossroads of acute and chronic inflammation Year: 2013 Erythropoietin (EPO) attenuates the immunohistochemical expression of tumor growth factor-ß (TGF-ß) in bleomycin (BLM)-induced pulmonary fibrosis (PF) in rats Source: International Congress 2018 – Pulmonary fibrosis: from models to patients Year: 2018 Thymosin beta4 protects mice from bleomycin-induced damage in the lung Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Therapeutic efficacy of a novel LPA1 receptor antagonist, UD-009, in a bleomycin-induced pulmonary fibrosis model Source: International Congress 2016 – Common mechanisms in lung development and fibrosis Year: 2016 Effect of nintedanib on the release of angiogenic/angiostatic cytokines by alveolar macrophages (AMs) in interstitial lung diseases (ILD) Source: International Congress 2015 – IPF: from bench to bedside Year: 2015